Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers
Authors:
- Iris GrossmanIGIris Grossman
- Nili AvidanNANili Avidan
- Clara SingerCSClara Singer
- Dan GoldstaubDGDan Goldstaub
- Liat HayardenyLHLiat Hayardeny
- Eli EyalEEEli Eyal
- Edna Ben-AsherEBEdna Ben-Asher
- Tamar PapernaTPTamar Paperna
- Itsik Pe'ErIPItsik Pe'Er
- Doron LancetDLDoron Lancet
- Jacques S. BeckmannJBJacques S. Beckmann
- Ariel MillerAMAriel Miller
- 1 August 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 17 (8) , 657-666
Abstract
Genetic-based optimization of treatment prescription is becoming a central research focus in the management of chronic diseases, such as multiple sclerosis, which incur a prolonged drug-regimen adjustment. This study was aimed to identify genetic markers that can predict response to glatiramer acetate (Copaxone) immunotherapy for relapsing multiple sclerosis. For this purpose, we genotyped fractional cohorts of two glatiramer acetate clinical trials for HLA-DRB1*1501 and 61 single nucleotide polymorphisms within a total of 27 candidate genes. Statistical analyses included single nucleotide polymorphism-by-single nucleotide polymorphism and haplotype tests of drug-by-genotype effects in drug-treated versus placebo-treated groups. We report the detection of a statistically significant association between glatiramer acetate response and a single nucleotide polymorphism in a T-cell receptor β (TRB@) variant replicated in the two independent cohorts (odds ratio=6.85). Findings in the Cathepsin S (CTSS) gene (P=0.049 corrected for all single nucleotide polymorphisms and definitions tested, odds ratio=11.59) in one of the cohorts indicate a possible association that needs to be further investigated. Additionally, we recorded nominally significant associations of response with five other genes, MBP, CD86, FAS, IL1R1 and IL12RB2, which are likely to be involved in glatiramer acetate's mode-of-action, both directly and indirectly. Each of these association signals in and of itself is consistent with the no-association null-hypothesis, but the number of detected associations is surprising vis-à-vis chance expectation. Moreover, the restriction of these associations to the glatiramer acetate-treated group, rather than the placebo group, clearly demonstrates drug-specific genetic effects. These findings provide additional progress toward development of pharmacogenetics-based personalized treatment for multiple sclerosis.Keywords
This publication has 38 references indexed in Scilit:
- Impact of Disease-Modifying Therapies on Brain and Spinal Cord Atrophy in Multiple SclerosisJournal of Neuroimaging, 2004
- Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison StudyMultiple Sclerosis Journal, 2004
- Glatiramer acetate for the treatment of multiple sclerosisExpert Opinion on Pharmacotherapy, 2004
- Multiple sclerosisJournal of Clinical Investigation, 2004
- Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trialsMultiple Sclerosis Journal, 2003
- Effect of glatiramer acetate on MS lesions enhancing at different gadolinium dosesNeurology, 2002
- The worldwide prevalence of multiple sclerosisClinical Neurology and Neurosurgery, 2002
- Pharmacogenetic development of personalized medicine: Multiple sclerosis treatment as a modelDrug News & Perspectives, 2002
- Mechanisms of action of glatiramer acetate in multiple sclerosisNeurology, 2001
- Pharmacogenetics and the practice of medicineNature, 2000